AbCellera Biologics Inc. ABCL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$43.17M+5.4% | -$8.95M+73.9% | -$57.12M-11.8% | -$34.73M+6.0% | -$45.62M-12.3% | ||
| $5.92M+34.2% | $5.18M+147% | $4.3M+13.2% | $4.5M+32.4% | $4.41M+39.7% | ||
| $12.01M-18.8% | $12.9M-15.3% | $13.9M-19.0% | $14.21M-20.1% | $14.79M-15.1% | ||
| -$9.41M-176% | $5.74M-13.2% | $5.07M+22.2% | -$3.95M-183% | -$3.41M+30.1% | ||
| $1.74M+124% | -$3.07M+37.9% | -$628K+74.7% | -$6.13M-188% | -$7.32M-303% | ||
| -$2.38M-7.4% | $4.32M— | -$1.66M-106% | $2.88M-70.9% | -$2.21M-29.6% | ||
| -$8.03M-160% | -$4.51M— | —— | —— | $13.31M+266% | ||
| -$4.97M-12.7% | -$10.05M-165% | -$12.2M-343% | -$3.18M-14.8% | -$4.41M-38.5% | ||
| $920K-0.2% | —— | $940K-97.2% | $929K-97.2% | $922K-45.4% | ||
| $1.82M+42.6% | $1.8M+34.5% | $1.99M+44.6% | $1.59M+4.9% | $1.27M-33.7% | ||
| -$13.1M-1,256% | $39.67M+90.1% | $3.43M-82.7% | $11.39M-28.2% | $1.13M-93.9% | ||
| —— | $7.53M— | $7.53M— | $7.53M— | $7.53M— | ||
| -$33.52M-190% | -$34.74M-334% | -$52.59M-82.1% | -$32.4M-8.1% | -$11.55M+72.3% | ||
| $3.83M-64.0% | $9.84M-37.0% | $8.93M-51.8% | $13.37M-33.5% | $10.64M-55.9% | ||
| —— | -$8.32M— | -$8.32M— | -$8.32M— | -$8.32M— | ||
| -$25.08M-416% | $75.14M+110% | $36.49M+887% | -$31.81M-161% | $7.94M-73.5% | ||
| $7.19M+20.5% | $4.12M-0.7% | $7.37M+134% | —— | $5.97M+111% | ||
| -$38K-106% | $290K+113% | —— | $761K+1,870% | $590K+176% | ||
| -$51.45M-1,849% | —— | -$9.28M+57.2% | -$66.83M-370% | $2.94M+130% | ||
| $920K-0.2% | $909K— | $940K-97.2% | $929K-97.2% | $922K-45.4% | ||
| $5.92M+34.2% | $5.18M+147% | $4.3M+13.2% | $4.5M+32.4% | $4.41M+39.7% | ||
| —— | $7.53M— | $7.53M— | $7.53M— | $7.53M— | ||
| —— | -$1.13M-107% | -$1.13M-107% | -$1.13M-107% | -$1.13M-107% | ||
| $2.36M+93.1% | $804K+124% | $1.15M+111% | $461K+105% | $1.22M+111% | ||
| -$8.03M-160% | -$4.51M— | —— | —— | $13.31M+266% | ||
| $1.74M+124% | -$3.07M+37.9% | -$628K+74.7% | -$6.13M-188% | -$7.32M-303% | ||
| $1.82M+42.6% | $1.8M+34.5% | $1.99M+44.6% | $1.59M+4.9% | $1.27M-33.7% | ||
| -$2.38M-7.4% | $4.32M— | -$1.66M-106% | $2.88M-70.9% | -$2.21M-29.6% | ||
| —— | -$8.32M— | -$8.32M— | -$8.32M— | -$8.32M— | ||
| $105K-98.6% | $322K— | $2.99M+131% | $6.3M+176% | $7.48M+70.7% | ||
| $1.36M+33.7% | $13.98M+113% | $918K-90.2% | $5.43M-56.8% | $1.02M-85.8% | ||
| —— | $7.43M+120% | $7.43M+120% | $7.43M+120% | $7.43M+120% | ||
| $7.19M+20.5% | —— | $7.55M+127% | $5.68M+101% | $5.97M+97.9% | ||
| -$37.35M-68.3% | -$44.59M-88.7% | -$61.52M-29.8% | -$45.77M+8.6% | -$22.19M+66.3% | ||
| -$37.35M-68.3% | -$44.59M-88.7% | -$61.52M-29.8% | -$45.77M+8.6% | -$22.19M+66.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does AbCellera Biologics Inc.'s cash flow data come from?
- Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.